Alchemia locks in new funding as it preps for oncology spin-off
This article was originally published in Scrip
The Australian drug discovery firm Alchemia has raised A$15 million ($15.5 million) in a placement to domestic and US institutional investors, part of which it will use to support the planned spin-off and listing of its cancer-related subsidiary Alchemia Oncology.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context